<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597220</url>
  </required_header>
  <id_info>
    <org_study_id>FORWARD</org_study_id>
    <nct_id>NCT00597220</nct_id>
  </id_info>
  <brief_title>Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation</brief_title>
  <acronym>FORWARD</acronym>
  <official_title>Randomized, Prospective, Placebo-controlled, Multi-center Study to Test the Efficacy of n-3 PUFA for the Maintenance of Normal Sinus Rhythm in Patients With Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion GESICA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion GESICA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that in patients with persistent atrial fibrillation who had recovered normal
      sinus rhythm and treated with the best recommended therapies, the addition of 1 gram / daily
      of n-3 PUFA is superior to the corresponding placebo for the maintenance of normal sinus
      rhythm at one year of follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) impose a substantial and growing economic burden on health care
      expenditures. In patients with persistent AF, there are fundamentally two ways to manage the
      arrhythmia: to restore and maintain sinus rhythm (rhythm control) or to allow AF to continue
      and ensure that the ventricular rate is controlled (rate control). As it has been stated, it
      goes without saying that if we could prevent atrial fibrillation (AF) or restore and maintain
      sinus rhythm in patients suffering from persistent AF, without any penalties due to the
      unwanted effects of drugs or incomplete suppression of AF and its thromboembolic
      complications, every physician would do so. Current strategies however, are limited to
      achieve such desirable goal. In the last years a growing amount of evidence and attention
      regarding the cardio-protective role of Omega 3 fatty acids (n-3 PUFA) became progressively
      clear and appealing.

      Epidemiological studies and randomized controlled trials confirms the role of n-3 PUFA in
      reducing all cause mortality and cardiovascular events mostly in patients at high
      cardiovascular risk. These effects seems to be mediated mostly by an anti-arrhythmogenic
      effect.

      Basic science confirms and extended clinical observations regarding the antiarrhythmogenic
      effect of these compounds. Recently both basic research and clinical science suggested a role
      of n-3 PUFA for the prevention and treatment of supraventricular arrhythmias, particularly
      AF.

      The purpose of the study is to show that the addition of n-3 PUFA on the top of the best
      recommended therapies can improve the maintenance of normal sinus rhythm in patients with
      persistent atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival free of atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in sinus rhythm at the time of each study visit</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for CV reasons</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all-cause hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TE events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who die or with non-fatal thromboembolic events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 (n-3 PUFA)</intervention_name>
    <description>1 gram of n-3 PUFA containing DHA and EPA</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent atrial fibrillation

        Exclusion Criteria:

          -  Contraindications or known hypersensitivity to n-3 PUFA

          -  Current treatment with n-3 PUFA for any reason

          -  Heart failure NYHA class IV

          -  Coronary artery bypass surgery or valve replacement within the past 3 months

          -  Planned cardiac procedures

          -  Known sick-sinus syndrome

          -  Diagnosis of Wolff-Parkinson-White

          -  Clinical significant valvular etiologies

          -  Presence of arrhythmia associated with an acute reversible condition

          -  Advanced chronic lung disease

          -  Contraindications for anticoagulation therapy

          -  Pregnancy or lactation

          -  Any non cardiac illness associated with a life expectancy of &lt; 2 years

          -  Treatment with any investigational agent within 3 month before randomization

          -  Any condition that in the opinion of the investigator would jeopardize the evaluation
             of efficacy or safety or be associated with poor adherence to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hernan C Doval, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianni Tognoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mario Negri Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Grancelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Varini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Nul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Macchia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Alemán</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Constituyentes</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Medico Policial Churruca Visca</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Favaloro</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Evita Pueblo FEDITEC</name>
      <address>
        <city>Lanus</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica y Maternidad Colon</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de la Comunidad</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMIC (Centro de Educación Médica e Investigaciones Clinicas Norberto Quirno)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Romagosa</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital José de San Martín</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Integral IOT</name>
      <address>
        <city>Misiones</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiovascular Salta</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alejandro Macchia</name_title>
    <organization>Fundacion GESICA</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

